Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomization, Open-label Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients

NCT06044493 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.

NCT NCT06044493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06044493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomization, Open-label Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients
Lead sponsor
Chong Kun Dang Pharmaceutical
Phase
Phase 4
Overall status
Completed
Start date
November 14, 2023
Completion date
October 29, 2025
Enrollment
158 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant